U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H30NO5
Molecular Weight 340.4345
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 1

SHOW SMILES / InChI
Structure of TROXONIUM

SMILES

CC[N+](CC)(CC)CCOC(=O)C1=CC(OC)=C(OC)C(OC)=C1

InChI

InChIKey=UDKQGBNUPIFBSJ-UHFFFAOYSA-N
InChI=1S/C18H30NO5/c1-7-19(8-2,9-3)10-11-24-18(20)14-12-15(21-4)17(23-6)16(13-14)22-5/h12-13H,7-11H2,1-6H3/q+1

HIDE SMILES / InChI

Molecular Formula C18H30NO5
Molecular Weight 340.4345
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Troxonium tosylate is a triethylcholine ester which resembles hemicholinium in some of its pharmacological effects. In animal pharmacological studies, it was noted that troxonium tosylate had a marked antitremorine activity with an associated hypotensive effect. This antitremorine activity, which is a common characteristic of antiparkinsonian agents, was found to be combined with an inhibitory function on acetylcholine synthesis and with a reduction of brain catecholamines. Troxonium tosylate was found to be an effective antiparkinsonian medication for drug-induced extrapyramidal manifestations. Troxonium tosylate caused a pronounced fall in the blood pressure in both normotensive and hypertensive animals. It produced this depressor effect mainly by antagonism of both central and peripheral autonomic ganglia. Troxonium did not possess atropine-like properties and was not active as an adrenergic blocker. Despite the potent effect upon the blood pressure, it did not significantly inhibit renal function and cardiac output. Because of its unique properties, it was postulated that troxonium might be of value in the management of hypertension of various etiologies.

Approval Year

PubMed

PubMed

TitleDatePubMed
A preliminary clinical study on an antihypertensive agent, troxonium tosylate.
1963 Jan 26
Troxonium tosylate in the treatment of drug-induced extrapyramidal manifestations.
1971 Apr
Troxonium tosylate in drug-induced Parkinsonism: a controlled comparative study.
1971 Sep-Oct

Sample Use Guides

A dose of 600 mg daily produced a significant fall in systolic and diastolic pressure relative to control levels in the hypertensives, while in the normotensives a dose of 600 mg produced no significant effect. A dosage of 1000 mg daily produced a significant fall in diastolic pressure from control levels in both these groups.
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Sat Dec 16 01:24:41 UTC 2023
Edited
by admin
on Sat Dec 16 01:24:41 UTC 2023
Record UNII
O3G618B085
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TROXONIUM
Common Name English
TROXONIUM ION
Common Name English
TROXONIUM CATION
Common Name English
TRIETHYL(2-HYDROXYETHYL)AMMONIUM 3,4,5-TRIMETHOXYBENZOATE
Systematic Name English
Code System Code Type Description
CAS
4386-76-9
Created by admin on Sat Dec 16 01:24:41 UTC 2023 , Edited by admin on Sat Dec 16 01:24:41 UTC 2023
PRIMARY
EPA CompTox
DTXSID00195965
Created by admin on Sat Dec 16 01:24:41 UTC 2023 , Edited by admin on Sat Dec 16 01:24:41 UTC 2023
PRIMARY
FDA UNII
O3G618B085
Created by admin on Sat Dec 16 01:24:41 UTC 2023 , Edited by admin on Sat Dec 16 01:24:41 UTC 2023
PRIMARY
PUBCHEM
417951
Created by admin on Sat Dec 16 01:24:41 UTC 2023 , Edited by admin on Sat Dec 16 01:24:41 UTC 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY